background
medic
editori
suggest
angiotensin
convert
enzym
inhibitor
acei
angiotensin
receptor
blocker
arb
given
peopl
arteri
hypertens
coronaviru
diseas
pandem
potenti
increas
risk
wors
clinic
outcom
calcium
channel
blocker
ccb
use
altern
method
use
cohort
case
populationbas
control
zheijang
china
test
role
usag
acei
arb
ccb
medic
risk
sever
covid
analys
adjust
age
sex
bmi
presenc
relev
comorbid
find
higher
bmi
diabet
cardio
cerebrovascular
diseas
independ
risk
factor
develop
individu
hypertens
take
ccb
significantli
increas
risk
odd
ratio
ci
manifest
symptom
wherea
take
arb
diuret
significantli
lower
diseas
risk
ci
ci
respect
antihypertens
drug
associ
increas
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
pandem
coronaviru
diseas
caus
new
zoonot
coronari
viru
sar
affect
million
peopl
caus
death
across
world
april
profound
impact
health
servic
public
health
clinic
spectrum
infect
appear
wide
encompass
asymptomat
infect
mild
upper
respiratori
tract
ill
fever
fatigu
cough
without
sputum
product
sever
viral
pneumonia
groundglass
opac
comput
tomographi
chest
lead
critic
ill
associ
respiratori
failur
septic
shock
multiorgan
failur
casefat
rate
rang
differ
region
larg
descript
studi
report
type
diabet
patient
hypertens
two
preval
comorbid
condit
moreov
diabet
hypertens
highli
preval
among
sever
manifest
patient
admit
intens
care
unit
die
diabet
none
studi
assess
effect
antihypertens
antidiabet
medic
sar
viru
bind
angiotensinconvert
enzym
human
express
broadli
includ
epitheli
cell
lung
intestin
kidney
heart
blood
vessel
viru
downregul
protein
express
replic
depend
manner
result
loss
function
whether
variat
express
contribut
virul
current
pandem
still
unclear
ongo
debat
whether
interact
viru
hypertens
may
influenc
manifest
covid
concern
rais
angiotensin
convert
enzym
inhibitor
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
acei
angiotensin
ii
type
receptor
blocker
arb
thiozolidinedion
often
prescrib
patient
diabet
hypertens
cardiac
diseas
may
increas
risk
clinic
outcom
contrast
counter
regulatori
enzym
degrad
angiotensin
ii
henc
reduc
effect
vasoconstrict
sodium
retent
fibrosi
therefor
trial
losartan
treatment
underway
enrol
patient
previous
receiv
treatment
acei
arb
investig
whether
antihypertens
antidiabet
medic
affect
either
develop
sever
use
multicent
cohort
patient
populationbas
control
subject
zhejiang
provinc
china
studi
protocol
conform
ethic
guidelin
declar
helsinki
local
ethic
committe
hospit
approv
retrospect
studi
cohort
requir
written
consent
waiv
due
retrospect
anonym
natur
studi
consecut
patient
present
hospit
zhejiang
provinc
china
jan
feb
confirm
diagnosi
infect
includ
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
transcriptasepolymerasechainreact
rtpcr
assay
nasal
pharyng
swab
specimen
laboratoryconfirm
case
includ
studi
clinic
data
patient
collect
electron
medic
record
patient
administ
antivir
support
treatment
prevent
complic
base
clinic
condit
sever
diseas
classifi
categori
accord
guidelin
diagnosi
treatment
new
coronaviru
pneumonia
fifth
edit
mild
type
patient
mild
clinic
symptom
pulmonari
chang
ct
imag
common
type
patient
symptom
fever
sign
respiratori
infect
pneumonia
chang
ct
imag
sever
type
patient
present
one
item
follow
respiratori
distress
respiratori
rate
b
oxygen
satur
finger
rest
condit
c
arteri
partial
pressur
oxygen
oxygen
concentr
mmhg
mmhg
kpa
critic
type
patient
meet
one
follow
criteria
respiratori
failur
requir
mechan
ventil
b
shock
c
requir
icu
admiss
requir
due
multipl
organ
failur
detail
method
data
sourc
use
establish
ehrbas
gener
populationbas
cohort
studi
eastern
coastal
area
china
describ
previous
control
group
use
current
studi
gener
popul
gulin
town
suburban
area
ningbo
citi
zhejiang
provinc
china
sinc
citizen
offer
regular
health
screen
gulin
health
center
detail
medic
histori
record
electron
medic
record
system
gulin
town
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
facilit
routin
primari
care
servic
local
gener
practition
gp
sinc
region
system
cover
nearli
healthrel
activ
resid
within
region
birth
death
includ
children
adolesc
pregnant
women
adult
elderli
peopl
perman
resid
cover
nation
health
insur
regist
health
inform
system
valid
healthcar
identifi
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
chronic
diseas
diagnos
doctor
gulin
outsid
gulin
report
ningbo
cdc
recheck
depart
chronic
diseas
manag
gulin
hospit
prescript
medicin
chronic
diseas
list
record
regularli
verifi
categor
variabl
express
frequenc
percentag
continu
variabl
express
mean
standard
deviat
logist
regress
carri
either
unadjust
adjust
covari
indic
tabl
legend
p
consid
statist
signific
select
studi
popul
illustr
figur
total
patient
enrol
admiss
variou
center
zheijiang
provinc
figur
populationbas
cohort
zhejiang
provinc
consist
adult
health
record
use
control
descript
characterist
comorbid
use
medic
avail
case
control
compar
tabl
find
preval
type
diabet
higher
bmi
presenc
cardiovascular
cerebrovascular
diseas
associ
increas
patient
tabl
adjust
factor
age
sex
bmi
case
antihypertens
adjust
hypertens
case
medic
use
treat
diabet
adjust
presenc
diseas
condit
associ
remain
statist
significantli
associ
adjust
age
sex
bmi
signific
differ
use
immunosuppress
medic
glucocorticoid
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
populationbas
control
significantli
higher
use
statin
among
covid
found
among
individu
diagnosi
hypertens
differ
use
angiotensin
convert
enzym
inhibitor
betablock
individu
significantli
like
calcium
channel
blocker
ccb
less
like
diuret
angiotensin
receptor
blocker
arb
also
find
adjust
demograph
presenc
use
antidiabet
medic
significantli
differ
patient
without
particularli
strike
use
glycosidas
inhibitor
significantli
less
preval
among
individu
infect
insulin
inhibitor
much
like
use
peopl
tabl
compar
figur
graphic
control
differ
sever
categori
figur
see
although
hypertens
preval
diagnos
individu
control
much
preval
sever
critic
case
tabl
figur
type
diabet
male
sex
age
show
similar
pattern
term
increas
preval
sever
tabl
figur
regard
antidiabet
medic
adjust
age
sex
bmi
diabet
glucosidas
inhibitor
less
preval
among
affect
individu
symptomat
dppinhibitor
insulin
much
preval
among
patient
compar
valu
sever
categori
figur
tabl
find
signific
associ
use
dppinhibitor
sever
adjust
age
sex
bmi
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
result
ci
insulin
observ
trend
higher
use
among
sever
case
ci
howev
achiev
statist
signific
tabl
carri
similar
analysi
antihypertens
medic
find
compar
populationbas
control
diagnos
individu
use
arb
diuret
significantli
less
preval
case
hypertens
among
hypertens
control
whilst
use
ccb
significantli
preval
among
case
control
adjust
age
sex
bmi
tabl
signific
differ
suscept
sever
seen
use
ace
inhibitor
figur
tabl
term
sever
trend
use
betablock
preval
sever
critic
case
mild
common
case
howev
adjust
age
sex
bmi
none
antihypertens
medic
significantli
associ
sever
figur
tabl
type
medic
remain
associ
sever
adjust
age
sex
bmi
immunosuppress
drug
glucocorticoid
ci
tabl
recent
descript
cohort
studi
report
type
diabet
patient
hypertens
two
preval
chronic
health
condit
use
casecontrol
design
involv
patient
wellcharacter
populationbas
control
southeast
region
china
identifi
higher
bmi
diabet
cardio
cerebrovascular
diseas
independ
risk
factor
develop
found
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
preval
hypertens
slightli
higher
among
patient
statist
signific
compar
preval
populationbas
control
group
furthermor
age
year
sex
male
bmi
associ
develop
sever
diseas
addit
adjust
age
sex
bmi
histori
hypertens
twofold
risk
develop
sever
form
analysi
medic
act
reninangiotensinaldosteron
system
demonstr
patient
significantli
less
like
compar
populationbas
control
take
arb
vs
diuret
vs
prior
present
adjust
covari
age
sex
bmi
well
presenc
hypertens
contrast
ccb
associ
increas
risk
although
hypertens
clearli
risk
factor
sever
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
type
receptor
concern
regard
acei
arb
led
call
discontinu
drug
prophylact
suspect
contrast
use
larg
longitudin
populationbas
control
group
multicentr
cohort
case
demonstr
arb
significantli
less
like
ci
develop
potenti
benefit
arb
context
may
relat
effect
gain
entri
type
ii
pneumocyt
downregul
lead
unab
angiotensin
ii
induc
organ
injuri
mous
model
induc
lung
injuri
could
limit
reninangiotensinaldosteron
system
blockad
analysi
nt
shown
acei
effect
similar
arb
consist
observ
acei
current
clinic
use
directli
affect
activ
awar
popul
base
casecontrol
studi
thu
far
investig
risk
factor
increas
suscept
howev
systemat
review
found
acei
reduc
risk
pneumonia
latter
studi
benefit
acei
substanti
greater
among
asian
patient
attribut
higher
preval
ace
polymorph
increas
acei
level
kinin
catabol
ethnic
group
develop
sever
critic
form
diseas
higher
proport
patient
mild
common
form
diseas
arb
compar
sever
critic
form
diseas
howev
neither
arb
acei
significantli
associ
sever
recent
retrospect
cohort
studi
wuhan
provinc
demonstr
lower
allcaus
mortal
among
patient
receiv
arb
acei
inhospit
compar
among
nt
receiv
drug
studi
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
power
evalu
effect
acei
vs
arb
addit
lower
proport
patient
overal
arb
acei
expect
rais
possibl
concern
regard
drug
begin
epidem
may
result
chang
medic
patient
admiss
inhospit
use
acei
previous
shown
associ
lower
rate
ventil
inhospit
mortal
viral
pneumonia
casecontrol
analysi
show
take
ccb
significantli
increas
risk
ci
manifest
symptom
addit
patient
betablock
like
develop
sever
critic
form
compar
mild
common
form
diseas
last
analysi
signific
adjust
age
sex
bmi
mechan
underli
find
unclear
evid
either
ccb
betablock
alter
express
one
studi
includ
hospitalis
pneumonia
bacteri
viral
case
show
increas
incid
major
cardiovascular
event
among
ccb
betablock
corticosteroid
impair
induct
antivir
type
interferon
respons
rang
respiratori
virus
well
describ
associ
corticosteroid
may
also
appli
context
explain
associ
drug
sever
infect
cohort
hypertens
strong
risk
factor
develop
sever
critic
form
independ
antihypertens
therapi
may
relat
higher
level
endothelin
hypertens
patient
effect
innat
immun
respons
strong
evid
innat
immun
respons
key
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
develop
sever
recent
data
suggest
macrophag
contribut
protect
hypertens
macrophag
deplet
augment
chronic
hypertens
respons
high
level
link
lung
damag
hiv
infect
thu
possibl
arteri
hypertens
link
higher
level
vasoconstrict
lower
blood
flow
may
contribut
lower
level
macrophag
ie
lower
innat
immun
respons
potenti
buildup
fluid
lung
pulmonari
oedema
relat
antidiabet
medic
find
disproportion
increas
intak
antidiabet
medic
dppinhibitor
insulin
amongst
patient
compar
control
group
howev
none
medic
significantli
associ
diseas
sever
higher
intak
antidiabet
medic
might
link
longer
durat
lower
glycaem
control
point
role
metabol
inflamm
predispos
individu
develop
sever
form
diseas
studi
number
strength
casecontrol
design
case
multipl
hospit
larg
prospect
populationbas
control
group
coverag
local
popul
provid
power
need
identifi
independ
risk
factor
includ
medic
use
assess
risk
factor
popul
includ
consecut
case
secondari
care
hospit
reflect
full
rang
casemix
seen
routin
clinic
practic
case
definit
assess
sever
adher
nation
guidelin
consist
across
center
involv
studi
limit
studi
includ
retrospect
natur
cohort
could
lead
possibl
underrecord
less
common
comorbid
drug
histori
particular
relat
use
glucocorticoid
even
though
includ
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
case
may
modest
power
evalu
potenti
risk
factor
low
frequenc
larg
case
seri
number
comorbid
cardiovascular
cerebrovascular
chronic
obstruct
pulmonari
diseas
infrequ
cancer
immunodefici
chronic
kidney
diseas
altogeth
form
case
patient
cardiovascular
comorbid
qualifi
angiotensinconvert
enzym
inhibitor
acei
angiotensin
ii
receptor
blocker
arb
therapi
howev
prescrib
pattern
drug
vari
wide
china
uk
acei
much
commonli
prescrib
although
much
larger
sampl
size
may
prove
signific
effect
real
compar
poorli
factor
contribut
sever
hypertens
use
immunosuppress
addit
low
casefat
rate
mean
abl
assess
risk
factor
associ
mortal
identifi
higher
bmi
diabet
cardio
cerebrovascular
diseas
independ
risk
factor
develop
prior
treatment
arb
diuret
associ
reduc
risk
ccb
increas
risk
develop
antihypertens
drug
associ
increas
risk
sever
critic
form
infect
found
evid
alter
arb
acei
therapi
context
pandem
patient
corticosteroid
higher
risk
develop
sever
form
therefor
monitor
close
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
error
bar
repres
ci
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
